Summary

The global radioligand therapy market is projected to reach USD 10.91 billion by 2035 from an estimated USD 3.15 billion in 2025, at a CAGR of 13.2% during the forecast period. The growth of the radioligand therapy market is majorly driven by increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, rising adoption of PSMA and SSTR PET imaging for patient selection, and expanding reimbursement coverage supporting broader patient access.

https://www.marketsandmarkets.com/Images/radioligand-therapy-rlt-market-Overview.webp

By target, the prostate-specific membrane antigen segment accounted for the largest market share in 2024.

Based on target, the market is categorized into Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), and other targets. The Prostate-Specific Membrane Antigen (PSMA) segment accounted for the largest share of the market in 2024. The large share of this segment is attributed to its high expression in prostate cancer cells and its minimal presence in normal tissues. This makes PSMA an ideal biomarker for precision oncology, enabling accurate patient selection and effective therapy delivery. The success of PSMA-targeted treatments, such as Pluvicto (lutetium-177 vipivotide tetraxetan), has reinforced its dominance, particularly in metastatic castration-resistant prostate cancer (mCRPC).

By product, the Lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market in 2024.
By product, the market is segmented into Lutetium?177 Vipivotide Tetraxetan, Lutetium-177 Dotatate, Radium-223 Dichloride, [LU-177]-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA ? I&T, I-131-1095, TLX591 (177LU Rosopatamab Tetraxetan), Alphamedix (???PB-DOTAMTATE), 67CU?SAR?BISPSMA, and other products. In 2024, the lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market. Developed and commercialized by Novartis, Lutetium-177 vipivotide tetraxetan (Pluvicto) targets Prostate-Specific Membrane Antigen (PSMA), a protein highly expressed in prostate cancer cells, making it a precision therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Since its FDA and EMA approvals, the therapy has become widely adopted due to its ability to extend survival and improve quality of life in patients with limited treatment options. Its use of lutetium-177 enables targeted beta radiation delivery, sparing surrounding healthy tissues while maximizing tumor control.

By region, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period.

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The key factors contributing to market growth include the rising cancer incidence, improvements in healthcare infrastructure, and increasing awareness of precision oncology solutions. Countries such as China, Japan, South Korea, India, and Australia are witnessing the growing adoption of nuclear medicine, which is supported by expanding diagnostic capabilities and investments in theragnostic. Governments & private institutions are actively investing in isotope production facilities, addressing long-standing supply challenges for key isotopes like lutetium-177 and actinium-225, essential for commercialized and pipeline RLT products. Regulatory authorities in the region also show greater receptivity to radiopharmaceutical approvals, creating a favourable environment for clinical development and faster patient access.

The primary interviews conducted for this report can be categorized as follows:

? By Respondent: Supply Side- 70% and Demand Side- 30%
? By Designation: Managers- 45%, CXO and Directors- 30%, and Executives- 25%
? By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%
Key Companies
The key players in the radioligand therapy market include Novartis AG (Switzerland), Bayer AG (Germany), Curium US LLC (US), Eli Lilly and Company (US), AstraZeneca plc (UK), Progenics Pharmaceuticals, Inc. (US), Ariceum Therapeutics GmbH (Germany), Telix Pharmaceuticals Limited (Australia), ITM Isotope Technologies Munich SE (Germany), Convergent Therapeutics, Inc. (US), Orano Med SAS (France), Actinium Pharmaceuticals, Inc. (US), Perspective Therapeutics, Inc. (US), Clarity Pharmaceuticals Ltd. (Australia), and Radiopharm Theranostics Ltd. (Australia), among others.
Research Coverage
This research report categorizes the radioligand therapy market, by product [Lutetium-177 vipivotide tetraxetan, LUTETIUM-177 DOTATATE, Radium-223 dichloride, (LU-177)-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA ? I&T, I-131-1095, TLX591 (177LU ROSOPATAMAB TETRAXETAN), ALPHAMEDIX (???PB-DOTAMTATE), 67CU?SAR?BISPSMA, and other products), target (PSMA, SSTR, and other targets), indication (prostate cancer, neuroendocrine tumors, and other indications), and end user (tertiary care academic/comprehensive cancer centers, specialized nuclear medicine centers, and other end user), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa).
The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the radioligand therapy market. A thorough analysis of the key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements: new approvals/launches, collaborations, acquisitions, and recent developments associated with the radioligand therapy market.
Reasons to buy this report
The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the radioligand therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
? Analysis of key drivers (increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, the rising adoption of PSMA and SSTR PET imaging for patient selection. Expanding reimbursement coverage supporting broader patient access), restraints (Isotope scarcity for Lu-177 and Ac-225 creating supply bottlenecks, complex regulatory requirements for handling & licensing radioactive materials, logistical hurdles & half-life constraints limiting distribution), opportunities [advancements of alpha therapies (Ac-225, Pb-212) with strong clinical potential, expansion into earlier-line and adjuvant use, broadening eligible populations, combination regimens with immuno-oncology, PARP inhibitors, and other targeted agents), and challenges (reactor outages and geopolitical risks impacting isotope production & supply chains and the growing competition from alternative modalities such as ADCs and bispecific antibodies)
? Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the radioligand therapy market
? Market Development: Comprehensive information about lucrative markets across varied regions
? Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the radioligand therapy market
? Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment & funding activities, brand/product comparative analysis, and vendor valuation & financial metrics of the radioligand therapy market.

ページTOPに戻る

Table of Contents

TABLE 1 RADIOLIGAND THERAPY MARKET: INCLUSIONS AND EXCLUSIONS 33
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 45
TABLE 3 RADIOLIGAND THERAPY MARKET: RISK ANALYSIS 48
TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FOR RADIOPHARMACEUTICAL MOLECULES BY REGION, 2023?2030 (USD BILLION) 59
TABLE 5 RADIOLIGAND THERAPY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 62
TABLE 6 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY KEY PLAYER, 2024 69
TABLE 7 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS,
BY REGION, 2024 70
TABLE 8 RADIOLIGAND THERAPY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 72
TABLE 9 RADIOLIGAND THERAPY MARKET: KEY CONFERENCES AND EVENTS, 2025?2027 76
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 14 RADIOLIGAND THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 81
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOLIGAND
THERAPY PRODUCTS (%) 83
TABLE 16 KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY, BY END USER 84
TABLE 17 HEALTH EXPENDITURE AND FINANCING, 2015?2024 (IN PERCENTAGE OF GDP) 86
TABLE 18 US: CANCER INCIDENCE, BY STATE, 2024 87
TABLE 19 RADIOLIGAND THERAPY PRODUCTS IN CLINICAL PIPELINE, 2025?2032 88
TABLE 20 US-ADJUSTED RECIPROCAL TARIFF RATES 92
TABLE 21 RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023?2035 (USD MILLION) 98
TABLE 22 RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN,
BY REGION, 2023?2035 (USD MILLION) 99
TABLE 23 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023?2035 (USD MILLION) 99
TABLE 24 EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023?2035 (USD MILLION) 100
TABLE 25 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023?2035 (USD MILLION) 100
TABLE 26 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023?2035 (USD MILLION) 101
TABLE 27 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY REGION, 2023?2035 (USD MILLION) 101
TABLE 28 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023?2035 (USD MILLION) 101
TABLE 29 RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY REGION, 2023?2035 (USD MILLION) 102
TABLE 30 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023?2035 (USD MILLION) 103
TABLE 31 EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE,
BY COUNTRY, 2023?2035 (USD MILLION) 103
TABLE 32 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE,
BY COUNTRY, 2023?2035 (USD MILLION) 104
TABLE 33 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023?2035 (USD MILLION) 104
TABLE 34 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE,
BY REGION, 2023?2035 (USD MILLION) 104
TABLE 35 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023?2035 (USD MILLION) 105
TABLE 36 RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY REGION, 2023?2035 (USD MILLION) 106
TABLE 37 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023?2035 (USD MILLION) 106
TABLE 38 EUROPE: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE,
BY COUNTRY, 2023?2035 (USD MILLION) 107
TABLE 39 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE,
BY COUNTRY, 2023?2035 (USD MILLION) 107
TABLE 40 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023?2035 (USD MILLION) 108
TABLE 41 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY REGION, 2023?2035 (USD MILLION) 108
TABLE 42 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023?2035 (USD MILLION) 108
TABLE 43 RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY REGION,
2023?2035 (USD MILLION) 109
TABLE 44 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002,
BY COUNTRY, 2023?2035 (USD MILLION) 109
TABLE 45 EUROPE: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023?2035 (USD MILLION) 110
TABLE 46 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002,
BY COUNTRY, 2023?2035 (USD MILLION) 110
TABLE 47 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002,
BY COUNTRY, 2023?2035 (USD MILLION) 111
TABLE 48 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002,
BY REGION, 2023?2035 (USD MILLION) 111
TABLE 49 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002,
BY COUNTRY, 2023?2035 (USD MILLION) 111
TABLE 50 RADIOLIGAND THERAPY MARKET FOR ???AC-PSMA-617, BY REGION,
2023?2035 (USD MILLION) 112
TABLE 51 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ???AC-PSMA-617,
BY COUNTRY, 2023?2035 (USD MILLION) 113
TABLE 52 EUROPE: RADIOLIGAND THERAPY MARKET FOR ???AC-PSMA-617, BY COUNTRY, 2023?2035 (USD MILLION) 113
TABLE 53 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ???AC-PSMA-617,
BY COUNTRY, 2023?2035 (USD MILLION) 114
TABLE 54 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ???AC-PSMA-617,0
BY COUNTRY, 2023?2035 (USD MILLION) 114
TABLE 55 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ???AC-PSMA-617, BY REGION, 2023?2035 (USD MILLION) 114
TABLE 56 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ???AC-PSMA-617,
BY COUNTRY, 2023?2035 (USD MILLION) 115
TABLE 57 RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION,
2023?2035 (USD MILLION) 116
TABLE 58 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023?2035 (USD MILLION) 116
TABLE 59 EUROPE: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY,
2023?2035 (USD MILLION) 117
TABLE 60 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023?2035 (USD MILLION) 117
TABLE 61 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023?2035 (USD MILLION) 118
TABLE 62 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION,
2023?2035 (USD MILLION) 118
TABLE 63 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023?2035 (USD MILLION) 118
TABLE 64 RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION,
2023?2035 (USD MILLION) 119
TABLE 65 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023?2035 (USD MILLION) 119
TABLE 66 EUROPE: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY,
2023?2035 (USD MILLION) 120
TABLE 67 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023?2035 (USD MILLION) 120
TABLE 68 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023?2035 (USD MILLION) 121
TABLE 69 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION, 2023?2035 (USD MILLION) 121
TABLE 70 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023?2035 (USD MILLION) 121
TABLE 71 RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION,
2023?2035 (USD MILLION) 122
TABLE 72 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023?2035 (USD MILLION) 123
TABLE 73 EUROPE: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY,
2023?2035 (USD MILLION) 123
TABLE 74 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY,
2023?2035 (USD MILLION) 124
TABLE 75 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023?2035 (USD MILLION) 124
TABLE 76 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION,
2023?2035 (USD MILLION) 124
TABLE 77 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023?2035 (USD MILLION) 125
TABLE 78 RADIOLIGAND THERAPY MARKET FOR ???PB-DOTAMTATE, BY REGION,
2023?2035 (USD MILLION) 126
TABLE 79 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ???PB-DOTAMTATE,
BY COUNTRY, 2023?2035 (USD MILLION) 126
TABLE 80 EUROPE: RADIOLIGAND THERAPY MARKET FOR ???PB-DOTAMTATE, BY COUNTRY, 2023?2035 (USD MILLION) 127
TABLE 81 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ???PB-DOTAMTATE,
BY COUNTRY, 2023?2035 (USD MILLION) 127
TABLE 82 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ???PB-DOTAMTATE,
BY COUNTRY, 2023?2035 (USD MILLION) 128
TABLE 83 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ???PB-DOTAMTATE,
BY REGION, 2023?2035 (USD MILLION) 128
TABLE 84 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ???PB-DOTAMTATE,
BY COUNTRY, 2023?2035 (USD MILLION) 128
TABLE 85 RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY REGION,
2023?2035 (USD MILLION) 129
TABLE 86 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA,
BY COUNTRY, 2023?2035 (USD MILLION) 130
TABLE 87 EUROPE: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023?2035 (USD MILLION) 130
TABLE 88 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA,
BY COUNTRY, 2023?2035 (USD MILLION) 131
TABLE 89 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA,
BY COUNTRY, 2023?2035 (USD MILLION) 131
TABLE 90 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA,
BY REGION, 2023?2035 (USD MILLION) 131
TABLE 91 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA,
BY COUNTRY, 2023?2035 (USD MILLION) 132
TABLE 92 RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY REGION,
2023?2035 (USD MILLION) 132
TABLE 93 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023?2035 (USD MILLION) 133
TABLE 94 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023?2035 (USD MILLION) 133
TABLE 95 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023?2035 (USD MILLION) 134
TABLE 96 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023?2035 (USD MILLION) 134
TABLE 97 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS,
BY REGION, 2023?2035 (USD MILLION) 134
TABLE 98 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023?2035 (USD MILLION) 135
TABLE 99 RADIOLIGAND THERAPY MARKET, BY TARGET, 2023?2035 (USD MILLION) 137
TABLE 100 RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023?2035 (USD MILLION) 138
TABLE 101 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023?2035 (USD MILLION) 138
TABLE 102 EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023?2035 (USD MILLION) 139
TABLE 103 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023?2035 (USD MILLION) 139
TABLE 104 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023?2035 (USD MILLION) 140
TABLE 105 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023?2035 (USD MILLION) 140
TABLE 106 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023?2035 (USD MILLION) 140
TABLE 107 RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023?2035 (USD MILLION) 141
TABLE 108 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023?2035 (USD MILLION) 142
TABLE 109 EUROPE: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR,
BY COUNTRY, 2023?2035 (USD MILLION) 142
TABLE 110 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023?2035 (USD MILLION) 143
TABLE 111 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023?2035 (USD MILLION) 143
TABLE 112 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023?2035 (USD MILLION) 143
TABLE 113 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023?2035 (USD MILLION) 144
TABLE 114 RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION,
2023?2035 (USD MILLION) 145
TABLE 115 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS,
BY COUNTRY, 2023?2035 (USD MILLION) 145
TABLE 116 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023?2035 (USD MILLION) 146
TABLE 117 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS,
BY COUNTRY, 2023?2035 (USD MILLION) 146
TABLE 118 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS,
BY COUNTRY, 2023?2035 (USD MILLION) 147
TABLE 119 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023?2035 (USD MILLION) 147
TABLE 120 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS,
BY REGION, 2023?2035 (USD MILLION) 147
TABLE 121 RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023?2035 (USD MILLION) 149
TABLE 122 RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY REGION,
2023?2035 (USD MILLION) 150
TABLE 123 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2023?2035 (USD MILLION) 150
TABLE 124 EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023?2035 (USD MILLION) 151
TABLE 125 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2023?2035 (USD MILLION) 151
TABLE 126 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2023?2035 (USD MILLION) 152
TABLE 127 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER,
BY REGION, 2023?2035 (USD MILLION) 152
TABLE 128 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2023?2035 (USD MILLION) 152
TABLE 129 RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023?2035 (USD MILLION) 153
TABLE 130 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023?2035 (USD MILLION) 154
TABLE 131 EUROPE: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS,
BY COUNTRY, 2023?2035 (USD MILLION) 154
TABLE 132 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023?2035 (USD MILLION) 155
TABLE 133 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023?2035 (USD MILLION) 155
TABLE 134 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023?2035 (USD MILLION) 155
TABLE 135 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023?2035 (USD MILLION) 156
TABLE 136 RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY REGION,
2023?2035 (USD MILLION) 156
TABLE 137 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023?2035 (USD MILLION) 157
TABLE 138 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023?2035 (USD MILLION) 157
TABLE 139 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023?2035 (USD MILLION) 158
TABLE 140 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023?2035 (USD MILLION) 158
TABLE 141 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS,
BY REGION, 2023?2035 (USD MILLION) 158
TABLE 142 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023?2035 (USD MILLION) 159
TABLE 143 RADIOLIGAND THERAPY MARKET, BY END USER, 2023?2035 (USD MILLION) 161
TABLE 144 RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION,
2023?2035 (USD MILLION) 162
TABLE 145 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY,
2023?2035 (USD MILLION) 162
TABLE 146 EUROPE: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY,
2023?2035 (USD MILLION) 163
TABLE 147 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY,
2023?2035 (USD MILLION) 163
TABLE 148 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY,
2023?2035 (USD MILLION) 164
TABLE 149 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION,
2023?2035 (USD MILLION) 164
TABLE 150 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY,
2023?2035 (USD MILLION) 165
TABLE 151 RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023?2035 (USD MILLION) 166
TABLE 152 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023?2035 (USD MILLION) 166
TABLE 153 EUROPE: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023?2035 (USD MILLION) 167
TABLE 154 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023?2035 (USD MILLION) 167
TABLE 155 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023?2035 (USD MILLION) 168
TABLE 156 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023?2035 (USD MILLION) 168
TABLE 157 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023?2035 (USD MILLION) 168
TABLE 158 RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY REGION,
2023?2035 (USD MILLION) 169
TABLE 159 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2023?2035 (USD MILLION) 170
TABLE 160 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023?2035 (USD MILLION) 170
TABLE 161 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2023?2035 (USD MILLION) 171
TABLE 162 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2023?2035 (USD MILLION) 171
TABLE 163 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS,
BY REGION, 2023?2035 (USD MILLION) 171
TABLE 164 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2023?2035 (USD MILLION) 172
TABLE 165 RADIOLIGAND THERAPY MARKET, BY REGION, 2023?2035 (USD MILLION) 174
TABLE 166 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 176
TABLE 167 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY,
2023?2035 (USD MILLION) 177
TABLE 168 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 177
TABLE 169 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 178
TABLE 170 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 178
TABLE 171 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 178
TABLE 172 US: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023?2035 (USD MILLION) 179
TABLE 173 US: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023?2035 (USD MILLION) 180
TABLE 174 US: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023?2035 (USD MILLION) 180
TABLE 175 US: RADIOLIGAND THERAPY MARKET, BY END USER, 2023?2035 (USD MILLION) 180
TABLE 176 CANADA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 181
TABLE 177 CANADA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 182
TABLE 178 CANADA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 182
TABLE 179 CANADA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 182
TABLE 180 EUROPE: KEY MACROECONOMIC INDICATORS 184
TABLE 181 EUROPE: RADIOLIGAND THERAPY MARKET, BY COUNTRY,
2023?2035 (USD MILLION) 184
TABLE 182 EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 185
TABLE 183 EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 185
TABLE 184 EUROPE: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 186
TABLE 185 EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 186
TABLE 186 GERMANY: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 187
TABLE 187 GERMANY: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 187
TABLE 188 GERMANY: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 188
TABLE 189 GERMANY: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 188
TABLE 190 UK: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023?2035 (USD MILLION) 189
TABLE 191 UK: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023?2035 (USD MILLION) 189
TABLE 192 UK: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023?2035 (USD MILLION) 190
TABLE 193 UK: RADIOLIGAND THERAPY MARKET, BY END USER, 2023?2035 (USD MILLION) 190
TABLE 194 FRANCE: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 191
TABLE 195 FRANCE: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 191
TABLE 196 FRANCE: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 192
TABLE 197 FRANCE: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 192
TABLE 198 ITALY: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023?2035 (USD MILLION) 193
TABLE 199 ITALY: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023?2035 (USD MILLION) 193
TABLE 200 ITALY: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 194
TABLE 201 ITALY: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 194
TABLE 202 SPAIN: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 195
TABLE 203 SPAIN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023?2035 (USD MILLION) 195
TABLE 204 SPAIN: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 196
TABLE 205 SPAIN: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 196
TABLE 206 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 197
TABLE 207 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 197
TABLE 208 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 198
TABLE 209 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 198TABLE 210 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 200
TABLE 211 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY COUNTRY,
2023?2035 (USD MILLION) 201
TABLE 212 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 201
TABLE 213 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 202
TABLE 214 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 202
TABLE 215 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 202
TABLE 216 CHINA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 203
TABLE 217 CHINA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023?2035 (USD MILLION) 204
TABLE 218 CHINA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 204
TABLE 219 CHINA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 204
TABLE 220 JAPAN: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 205
TABLE 221 JAPAN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023?2035 (USD MILLION) 206
TABLE 222 JAPAN: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 206
TABLE 223 JAPAN: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 206
TABLE 224 INDIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023?2035 (USD MILLION) 207
TABLE 225 INDIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023?2035 (USD MILLION) 208
TABLE 226 INDIA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 208
TABLE 227 INDIA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 208
TABLE 228 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 209
TABLE 229 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 210
TABLE 230 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 210
TABLE 231 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 210
TABLE 232 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 211
TABLE 233 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 212
TABLE 234 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 212
TABLE 235 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 212
TABLE 236 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 213
TABLE 237 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 214
TABLE 238 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 214
TABLE 239 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 214
TABLE 240 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 216
TABLE 241 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY,
2023?2035 (USD MILLION) 216
TABLE 242 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 217
TABLE 243 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 217
TABLE 244 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 218
TABLE 245 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 218
TABLE 246 BRAZIL: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 219
TABLE 247 BRAZIL: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023?2035 (USD MILLION) 219
TABLE 248 BRAZIL: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 220
TABLE 249 BRAZIL: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 220
TABLE 250 MEXICO: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 221
TABLE 251 MEXICO: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 221
TABLE 252 MEXICO: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 222
TABLE 253 MEXICO: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 222
TABLE 254 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 223
TABLE 255 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 223
TABLE 256 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 224
TABLE 257 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 224
TABLE 258 MIDDLE EAST: KEY MACROECONOMIC INDICATORS 226
TABLE 259 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY REGION,
2023?2035 (USD MILLION) 226
TABLE 260 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 227
TABLE 261 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 227
TABLE 262 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 228
TABLE 263 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 228
TABLE 264 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY COUNTRY,
2023?2035 (USD MILLION) 229
TABLE 265 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 229
TABLE 266 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 230
TABLE 267 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 230
TABLE 268 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 230
TABLE 269 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 231
TABLE 270 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 232
TABLE 271 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 232
TABLE 272 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 232
TABLE 273 UAE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023?2035 (USD MILLION) 233
TABLE 274 UAE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023?2035 (USD MILLION) 234
TABLE 275 UAE: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 234
TABLE 276 UAE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023?2035 (USD MILLION) 234
TABLE 277 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 235
TABLE 278 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 236
TABLE 279 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023?2035 (USD MILLION) 236
TABLE 280 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 236
TABLE 281 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 237
TABLE 282 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023?2035 (USD MILLION) 238
TABLE 283 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 238
TABLE 284 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 238
TABLE 285 AFRICA: KEY MACROECONOMIC INDICATORS 240
TABLE 286 AFRICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023?2035 (USD MILLION) 240
TABLE 287 AFRICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023?2035 (USD MILLION) 241
TABLE 288 AFRICA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023?2035 (USD MILLION) 241
TABLE 289 AFRICA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023?2035 (USD MILLION) 241
TABLE 290 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN RADIOLIGAND THERAPY MARKET, 2023?2025 242
TABLE 291 RADIOLIGAND THERAPY MARKET: DEGREE OF COMPETITION 245
TABLE 292 RADIOLIGAND THERAPY MARKET: REGION FOOTPRINT 251
TABLE 293 RADIOLIGAND THERAPY MARKET: TARGET FOOTPRINT 252
TABLE 294 RADIOLIGAND THERAPY MARKET: INDICATION FOOTPRINT 252
TABLE 295 RADIOLIGAND THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 255
TABLE 296 RADIOLIGAND THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 256
TABLE 297 RADIOLIGAND THERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022?AUGUST 2025 257
TABLE 298 RADIOLIGAND THERAPY MARKET: DEALS, JANUARY 2022?AUGUST 2025 258
TABLE 299 RADIOLIGAND THERAPY MARKET: EXPANSIONS, JANUARY 2022?AUGUST 2025 259
TABLE 300 NOVARTIS AG: COMPANY OVERVIEW 260
TABLE 301 NOVARTIS AG: PRODUCTS OFFERED 261
TABLE 302 NOVARTIS AG: PRODUCTS IN PIPELINE 262
TABLE 303 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022?AUGUST 2025 262
TABLE 304 NOVARTIS AG: DEALS, JANUARY 2022?AUGUST 2025 262
TABLE 305 NOVARTIS AG: EXPANSIONS, JANUARY 2022?AUGUST 2025 263
TABLE 306 BAYER AG: COMPANY OVERVIEW 265
TABLE 307 BAYER AG: PRODUCTS OFFERED 266
TABLE 308 BAYER AG: DEALS, JANUARY 2022?AUGUST 2025 267
TABLE 309 BAYER AG: OTHER DEVELOPMENTS, JANUARY 2022?AUGUST 2025 267
TABLE 310 CURIUM US LLC: COMPANY OVERVIEW 269
TABLE 311 CURIUM US LLC: PRODUCTS IN PIPELINE 269
TABLE 312 CURIUM US LLC: DEALS, JANUARY 2022?AUGUST 2025 269
TABLE 313 ELI LILLY AND COMPANY: COMPANY OVERVIEW 271
TABLE 314 ELI LILLY AND COMPANY: PRODUCTS IN PIPELINE 272
TABLE 315 ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022? AUGUST 2025 273
TABLE 316 ELI LILLY AND COMPANY: DEALS, JANUARY 2022?AUGUST 2025 273
TABLE 317 ASTRAZENECA: COMPANY OVERVIEW 275
TABLE 318 ASTRAZENECA: PRODUCTS IN PIPELINE 276
TABLE 319 ASTRAZENECA: DEALS, JANUARY 2022?AUGUST 2025 277
TABLE 320 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY OVERVIEW 278
TABLE 321 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): PRODUCTS IN PIPELINE 279
TABLE 322 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): DEALS,
JANUARY 2022?AUGUST 2025 279
TABLE 323 ARICEUM THERAPEUTICS: COMPANY OVERVIEW 280
TABLE 324 ARICEUM THERAPEUTICS: PRODUCTS IN PIPELINE 280
TABLE 325 ARICEUM THERAPEUTICS: DEALS, JANUARY 2022?AUGUST 2025 280
TABLE 326 TELIX PHARMACEUTICALS: COMPANY OVERVIEW 281
TABLE 327 TELIX PHARMACEUTICALS: PRODUCTS IN PIPELINE 282
TABLE 328 TELIX PHARMACEUTICALS: DEALS, JANUARY 2022?AUGUST 2025 283
TABLE 329 TELIX PHARMACEUTICALS: EXPANSIONS, JANUARY 2022?AUGUST 2025 283
TABLE 330 TELIX PHARMACEUTICAL: OTHER DEVELOPMENTS, JANUARY 2022?AUGUST 2025 283
TABLE 331 ITM ISOTOPE TECHNOLOGIES: COMPANY OVERVIEW 284
TABLE 332 ITM ISOTOPE TECHNOLOGIES: PRODUCTS OFFERED 284
TABLE 333 ITM ISOTOPE TECHNOLOGIES: DEALS, JANUARY 2022?AUGUST 2025 285
TABLE 334 ITM ISOTOPE TECHNOLOGIES: EXPANSIONS, JANUARY 2022?AUGUST 2025 286
TABLE 335 CONVERGENT THERAPEUTICS, INC.: COMPANY OVERVIEW 287
TABLE 336 CONVERGENT THERAPEUTICS, INC.: PRODUCTS IN PIPELINE 287
TABLE 337 CONVERGENT THERAPEUTICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022?AUGUST 2025 287
TABLE 338 CONVERGENT THERAPEUTICS, INC.: DEALS, JANUARY 2022?AUGUST 2025 288
TABLE 339 ORANO SA: COMPANY OVERVIEW 289
TABLE 340 ORANO SA: PRODUCTS IN PIPELINE 290
TABLE 341 ORANO SA: DEALS, JANUARY 2022?AUGUST 2025 291
TABLE 342 ORANO SA: EXPANSIONS, JANUARY 2022?AUGUST 2025 291
TABLE 343 ACTINIUM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 292
TABLE 344 ACTINIUM PHARMACEUTICALS, INC.: PRODUCTS IN PIPELINE 293
TABLE 345 ACTINIUM PHARMACEUTICALS, INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022?AUGUST 2025 293
TABLE 346 ACTINIUM PHARMACEUTICALS, INC.: DEALS, JANUARY 2022?AUGUST 2025 293
TABLE 347 PERSPECTIVE THERAPEUTICS, INC.: COMPANY OVERVIEW 2

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 RADIOLIGAND THERAPY MARKET SEGMENTATION AND REGIONAL SCOPE 32
FIGURE 2 RADIOLIGAND THERAPY MARKET: YEARS CONSIDERED 33
FIGURE 3 RADIOLIGAND THERAPY MARKET: RESEARCH DESIGN 35
FIGURE 4 RADIOLIGAND THERAPY MARKET: KEY DATA FROM SECONDARY SOURCES 37
FIGURE 5 RADIOLIGAND THERAPY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 38
FIGURE 6 RADIOLIGAND THERAPY MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2024 39
FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2030 40
FIGURE 8 REVENUE SHARE ANALYSIS OF NOVARTIS, 2024 40
FIGURE 9 RADIOLIGAND THERAPY MARKET SIZE VALIDATION FROM PRIMARY SOURCES 42
FIGURE 10 RADIOLIGAND THERAPY MARKET: TOP-DOWN APPROACH 43
FIGURE 11 RADIOLIGAND THERAPY MARKET: CAGR PROJECTIONS 44
FIGURE 12 RADIOLIGAND THERAPY MARKET: DATA TRIANGULATION 46
FIGURE 13 RADIOLIGAND THERAPY MARKET: GLOBAL MARKET SIZE, GROWTH
RATE, AND FORECAST 49
FIGURE 14 RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2025 VS. 2035 (USD MILLION) 51
FIGURE 15 RADIOLIGAND THERAPY MARKET, BY TARGET, 2025 VS. 2035 (USD MILLION) 52
FIGURE 16 RADIOLIGAND THERAPY MARKET, BY INDICATION, 2025 VS. 2035 (USD MILLION) 52
FIGURE 17 RADIOLIGAND THERAPY MARKET, BY END USER, 2025 VS. 2035 (USD MILLION) 53
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF RADIOLIGAND THERAPY MARKET 54
FIGURE 19 INCREASING APPROVALS AND LABEL EXPANSION OF RLT PRODUCTS
TO DRIVE MARKET 55
FIGURE 20 LUTETIUM?177 VIPIVOTIDE TETRAXETAN SEGMENT AND US TO LEAD NORTH AMERICAN MARKET IN 2024 56
FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 57
FIGURE 22 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATE DURING
FORECAST PERIOD 58
FIGURE 23 RADIOLIGAND THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 61
FIGURE 24 NEW REVENUE POCKETS FOR PLAYERS IN RADIOLIGAND THERAPY MARKET 67
FIGURE 25 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS,
BY KEY PLAYER, 2024 68
FIGURE 26 INDICATIVE PRICING ANALYSIS, BY REGION, 2024 69
FIGURE 27 RADIOLIGAND THERAPY MARKET: VALUE CHAIN ANALYSIS 70
FIGURE 28 RADIOLIGAND THERAPY MARKET: ECOSYSTEM ANALYSIS 72
FIGURE 29 RADIOLIGAND THERAPY MARKET: INVESTMENT AND FUNDING SCENARIO,
2023?2024 73
FIGURE 30 RADIOLIGAND THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 81
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOLIGAND
THERAPY PRODUCTS 83
FIGURE 32 KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY PRODUCTS, BY END USER 84
FIGURE 33 RADIOLIGAND THERAPY MARKET: AI USE CASES 91
FIGURE 34 NORTH AMERICA: RADIOLIGAND THERAPY MARKET SNAPSHOT 176
FIGURE 35 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET SNAPSHOT 200
FIGURE 36 RADIOLIGAND THERAPY MARKET: REVENUE ANALYSIS OF KEY PLAYERS,
2028?2030 (USD MILLION) 244
FIGURE 37 RADIOLIGAND THERAPY MARKET SHARE ANALYSIS OF KEY PLAYERS, 2030 245
FIGURE 38 EV/EBITDA OF KEY VENDORS 246
FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 247
FIGURE 40 RADIOLIGAND THERAPY MARKET: BRAND/PRODUCT COMPARISON 247
FIGURE 41 RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 249
FIGURE 42 RADIOLIGAND THERAPY MARKET: COMPANY FOOTPRINT 250
FIGURE 43 RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 254
FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT (2024) 261
FIGURE 45 BAYER AG: COMPANY SNAPSHOT (2024) 266
FIGURE 46 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024) 272
FIGURE 47 ASTRAZENECA: COMPANY SNAPSHOT (2024) 276
FIGURE 48 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY SNAPSHOT (2024) 278
FIGURE 49 TELIX PHARMACEUTICALS: COMPANY SNAPSHOT (2024) 282
FIGURE 50 ORANO SA: COMPANY SNAPSHOT (2024) 290
FIGURE 51 ACTINIUM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023) 292
FIGURE 52 CLARITY PHARMACEUTICALS: COMPANY SNAPSHOT (2024) 296